NZ571615A - Quinazolinone derivatives and their use as CB agonists - Google Patents

Quinazolinone derivatives and their use as CB agonists

Info

Publication number
NZ571615A
NZ571615A NZ571615A NZ57161503A NZ571615A NZ 571615 A NZ571615 A NZ 571615A NZ 571615 A NZ571615 A NZ 571615A NZ 57161503 A NZ57161503 A NZ 57161503A NZ 571615 A NZ571615 A NZ 571615A
Authority
NZ
New Zealand
Prior art keywords
compound
formula
dimethyl
hydrogen
oxo
Prior art date
Application number
NZ571615A
Other languages
English (en)
Inventor
Christopher Thomas Brain
Edward Karol Dziadulewicz
Terance William Hart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ571615A publication Critical patent/NZ571615A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ571615A 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as CB agonists NZ571615A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound

Publications (1)

Publication Number Publication Date
NZ571615A true NZ571615A (en) 2010-01-29

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ571615A NZ571615A (en) 2002-02-06 2003-02-05 Quinazolinone derivatives and their use as CB agonists

Country Status (21)

Country Link
US (2) US20050085493A1 (https=)
EP (2) EP1472234B1 (https=)
JP (2) JP4428479B2 (https=)
KR (1) KR100954626B1 (https=)
CN (1) CN100579968C (https=)
AR (1) AR038483A1 (https=)
AT (1) ATE551329T1 (https=)
AU (1) AU2003210212A1 (https=)
BR (1) BR0307461A (https=)
CA (1) CA2471974C (https=)
CO (1) CO5601021A2 (https=)
EC (1) ECSP045219A (https=)
ES (1) ES2384967T3 (https=)
MX (1) MXPA04007641A (https=)
MY (1) MY143958A (https=)
NO (1) NO328305B1 (https=)
NZ (1) NZ571615A (https=)
PE (1) PE20030867A1 (https=)
PL (1) PL370657A1 (https=)
TW (1) TW200306839A (https=)
WO (1) WO2003066603A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2260007C2 (ru) 1999-03-17 2005-09-10 Астразенека Аб Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
AU2004289638B2 (en) 2003-11-04 2009-10-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
US20090029984A1 (en) * 2005-07-11 2009-01-29 N.V. Organon Synergistic combination for the treatment of pain (cannabinoid receptor agonist and opioid receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての２，７−ジアザ−スピロ［４，５］デカ−７−イル誘導体のｌ−リンゴ酸塩およびその結晶形態
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用
CN109796360B (zh) * 2019-01-30 2022-03-18 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (https=) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
NZ192392A (en) * 1978-12-19 1983-02-15 M Ishikawa 3-(substituted (phenyl or pyridyl)) -3,4-dihydroquinazolin-4-ones
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
JPH07508030A (ja) * 1992-05-13 1995-09-07 アルコン　ラボラトリーズ，インコーポレイテッド カルシウムアンタゴニストと公知の抗緑内障薬との組合せを含む眼局所用組成物
EP0887340A4 (en) 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR100954626B1 (ko) 2010-04-27
CA2471974A1 (en) 2003-08-14
ECSP045219A (es) 2004-09-28
NO328305B1 (no) 2010-01-25
CA2471974C (en) 2011-11-22
JP2009149658A (ja) 2009-07-09
PL370657A1 (en) 2005-05-30
MXPA04007641A (es) 2004-11-10
EP2319839A1 (en) 2011-05-11
ATE551329T1 (de) 2012-04-15
BR0307461A (pt) 2004-11-09
PE20030867A1 (es) 2003-12-04
NO20043580D0 (no) 2004-08-27
HK1079518A1 (zh) 2006-04-07
US20070265285A1 (en) 2007-11-15
CN100579968C (zh) 2010-01-13
JP2005522439A (ja) 2005-07-28
WO2003066603A1 (en) 2003-08-14
AR038483A1 (es) 2005-01-19
ES2384967T3 (es) 2012-07-16
US20050085493A1 (en) 2005-04-21
EP1472234A1 (en) 2004-11-03
JP4428479B2 (ja) 2010-03-10
MY143958A (en) 2011-07-29
KR20040083501A (ko) 2004-10-02
EP1472234B1 (en) 2012-03-28
TW200306839A (en) 2003-12-01
CO5601021A2 (es) 2006-01-31
NO20043580L (no) 2004-09-21
US8552015B2 (en) 2013-10-08
AU2003210212A1 (en) 2003-09-02
CN1628104A (zh) 2005-06-15

Similar Documents

Publication Publication Date Title
US8552015B2 (en) Quinazolinone derivatives and their use as CB agonists
JP3814125B2 (ja) ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
SK7972000A3 (en) 2-aryl-8-oxodihydropurine derivatives, process for producing the same, medicinal compositions containing the same, and intermediates thereof
CN103974955B (zh) 嘧啶并-哒嗪酮化合物及其用途
NZ554211A (en) Substituted 2H-1,3-Benzoxazin-4(3H)-ones
El Kayal et al. Synthesis, in vivo and in silico anticonvulsant activity studies of new derivatives of 2-(2, 4-dioxo-1, 4-dihydroquinazolin-3 (2H)-yl) acetamide
JP2019520327A (ja) Ｔｒｐｖ４拮抗薬
JP2017515845A (ja) カルボキサミド誘導体
TW530055B (en) Atropisomers 3-heteroaryl-4(3H)-quinazolinones
KR100304177B1 (ko) (1,2,4)트리아졸로(4,3-a)퀴녹살린화합물,이의제조방법및이를함유하는약제학적조성물_
AU2007202781B2 (en) Quinazolinone derivatives and their use as CB agonists
WO2015148465A1 (en) Pyrazole compounds selective for neurotensin 2 receptor
CA2755968C (en) Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof
FI102276B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 5-N,N-dialkyylisulfa moyyli-1H-6,7,8,9-tetrahydro£g|indoli-2,3-dioni-3-oksiimien valmistami seksi
ZA200404959B (en) Quinazolinone derivatives and their use as CB agonists
CN101228131A (zh) 新的杂环亚基乙酰胺衍生物
HK1079518B (en) Quinazolinone derivatives and their use as cb agonists
HUT73438A (en) Quinoxalin-2,3-dione derivatives pericondensed with heterocycle
JP2023531097A (ja) テトラヒドロイソキノリン類誘導体の塩、その製造方法及びその医薬学的応用
JP2024534282A (ja) 治療剤として使用するための転写因子ｂｒｎ２阻害性化合物
HK1245795B (en) Fused bicyclic compounds for the treatment of disease
CZ20001981A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty, způsob jejich přípravy, farmaceutické prostředky které je obsahují a jejich meziprodukty
KR19990071056A (ko) Nmda 수용체 길항제로 작용하는 4-치환-퀴놀린-2-카복실산유도체

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed